소포스부비르

한글명:소포스부비르

카스 번호1190307-88-0

상품명:Sofosbuvir

CBNumberCB02604350

분자식C22H29FN3O9P

포뮬러 무게529.45

MOL 파일1190307-88-0.mol

동의어(한글)

소포스부비르

화학적 성질

녹는점	122-124°C
밀도	1.41
저장 조건	Hygroscopic, -20°C Freezer, Under inert atmosphere
용해도	DMSO(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태	고체
물리적 상태	단단한 모양
산도 계수 (pKa)	9.39±0.10(Predicted)
색상	하얀색
InChIKey	TTZHDVOVKQGIBA-YBSJRAAASA-N
SMILES	C(OC(C)C)(=O)[C@@H](N[P@@](OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(OC1=CC=CC=C1)=O)C
CAS 데이터베이스	1190307-88-0

위험 및 안전 성명

HS 번호

29339900

유해 물질 데이터

1190307-88-0(Hazardous Substances Data)

NFPA 704:

	0
2		0

그림문자(GHS)

소포스부비르 화학적 특성, 용도, 생산

개요
Sofosbuvir is a drug used for the treatment of hepatitis C. It is recommended to be used in combination with other drugs (such as velpatasvir) for the first-line treatment for HCV genotypes 1, 2, 3, 4, 5, and 6. It takes effect through acting as a nucleotide analog inhibitor, being capable of specially inhibiting the HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase.
용도
PSI-7977 is a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the t reatment of hepatitis C. Studies have profiled PSI-7977 as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.
정의
ChEBI: A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.
Clinical Use
In December 2013, sofosbuvir (also known as GS-7977 and PSI-7977) was approved in the United States for the treatment of hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen. Sofosbuvir was discovered from an effort to enhance the activity of the parent nucleoside by bypassing rate-limiting monophosphorylation with a prodrug that would liberate the intactmonophosphate in the liver, where it would then be converted by cellular kinases to the active triphosphate species. In addition, the prodrug was designed to be amenable to oral delivery. In the initial synthesis of sofosbuvir, the iso-propyl ester of (L)-alanine was coupled with phenyl dichlorophosphate to provide a diastereomeric intermediate that was coupled with the uridine nucleoside. The diastereomeric mixture (GS-9851) was shown to produce high levels of triphosphate in vitro in primary hepatocytes and in the livers of rats, dogs, and monkeys after oral dosing. The individual diastereomers were obtained by chromatography or by crystallization. The diastereomer with the Sp configuration at the phosphorous center (sofosbuvir) was found to be >10-fold more potent in an HCV replicon assay than the corresponding Rp diastereomer (EC_90s of 0.42 and 7.5 μM, respectively).

소포스부비르 준비 용품 및 원자재

소포스부비르 공급 업체

Send Inquriy